All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	==Medical uses== The 2022 [[American Diabetes Association\|ADA]] standards of medical care in diabetes include SGLT2 inhibitors as a first line [[pharmacological therapy]] for type 2 diabetes (usually together with metformin), specifically in patients with [[chronic kidney disease]], [[cardiovascular disease]] or [[heart failure]].
^h Japanese (ja)	==医薬用途== {{Anchor\|Medical uses}} 2022年の[[American Diabetes Association/ja\|ADA]]の糖尿病診療標準では、SGLT2阻害薬は2型糖尿病のファーストライン[[pharmacological therapy/ja\|薬物療法]]として（通常はメトホルミンと併用する）、特に[[chronic kidney disease/ja\|慢性腎臓病]]、[[cardiovascular disease/ja\|心血管疾患]]、[[heart failure/ja\|心不全]]を有する患者に使用されている。